(RTTNews) - Ipsen (IPSEY) announced confirmation of an expanded collaboration and license agreement with Exelixis for the development of Cabometyx (cabozantinib) in advanced pancreatic neuroendocrine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results